source
- Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapiesEli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
- Eli Lilly makes 14th acquisition of 2026, buying a blood-cancer biotechEli Lilly announced it has acquired a blood‑cancer focused biotechnology company, marking its 14th acquisition in 2026. The deal reflects Lilly’s aggressive expansion strategy, funded by strong sa…